Wed, May 14, 10:15 AM (60 days ago)
**DarioHealth Corp. (DRIO) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $6,752,000 (up 17.3% YoY) - **Gross Profit:** $3,882,000 (57.5% of revenues) - **Operating Loss:** $9,409,000 - **Net Loss:** $9,227,000 (up 28.6% YoY) - **Cash & Cash Equivalents:** $27,854,000 **Profit Margins:** - **Gross Margin:** 57.5% - **Operating Margin:** -139.1% **Cash Flow:** - **Operating Cash Flow:** -$6,673,000 - **Investing Cash Flow:** -$31,000 - **Financing Cash Flow:** $6,815,000 **Earnings Changes:** - **Revenue Increase:** 17.3% YoY - **Net Loss Increase:** 28.6% YoY **Quarterly Performance Discussion:** - **Revenue Growth:** Driven by commercial channel. - **Cost Reduction:** Decrease in amortization of technology and payroll costs. - **Operating Expenses:** Decrease in R&D, sales & marketing, and G&A expenses. - **Cash Flow:** Improved operating cash flow but still negative. **Trends & Uncertainties:** - **Revenue Concentration:** Major customer accounts for 19.1% of revenue. - **Geopolitical Risks:** Operations in Israel face political and military instability. - **Regulatory Risks:** Nasdaq compliance and potential delisting. - **Market Volatility:** Stock price fluctuations and potential impairment of intangible assets. **Future Operations Impact:** - **Debt Refinancing:** New $32,500,000 credit facility to support growth. - **Strategic Partnerships:** New clients and collaborations to drive revenue. - **Research & Development:** Continued investment in digital therapeutics and AI. **Management's Outlook:** - **Revenue Growth:** Targeting 40 new clients in 2025. - **Cost Management:** Focus on reducing operating expenses. - **Funding:** Seeking additional capital for long-term development and commercialization. **Ticker:** DRIO